VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$70.63 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2020 was -$70.63M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2019 was -$56.32M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2018 was -$49.04M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2017 was -$21.45M, a 615.45% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2020-12-31 | -$70.63M 10-K · filed 2021-02-11 |
| 2019-12-31 | -$56.32M 10-K · filed 2021-02-11 |
| 2018-12-31 | -$49.04M 10-K · filed 2021-02-11 |
| 2017-12-31 | -$21.45M 10-K · filed 2020-02-13 |
| 2016-12-31 | $4.16M 10-K · filed 2019-02-13 |
| 2015-12-31 | $951.00K 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |